Our donors

The work IAVI does would not be possible without the generous donors, individuals, and partners around the world who have supported our mission for more than two decades. Over the last 25 years, IAVI has been fortunate to receive funding from a diverse array of supporters, including government agencies, philanthropic organizations, and academic institutions. We gratefully acknowledge all who have supported us along the way, and together, we look forward to a future where all people have equitable access to innovative vaccines and therapeutics.


The Bill & Melinda Gates Foundation

IAVI recognizes the Bill & Melinda Gates Foundation’s long-standing commitment to HIV vaccine research and applauds their leadership in the fight against infectious diseases.

The Bill & Melinda Gates Foundation has been an instrumental partner for IAVI for over two decades. This support began in 1998 with an award of US$1.5 million from what was then the William H. Gates Foundation, which was soon followed in 1999 with an award of $25 million  to develop IAVI’s HIV vaccine portfolio. In 2001, a generous $100 million challenge grant was then provided to mobilize global support for IAVI’s Scientific Blueprint.

Over the years, the Bill & Melinda Gates Foundation has engaged in key partnerships that have leveraged significant support for IAVI, including a joint effort with the National Institutes of Health (NIH) in 2005 to pledge up to $660 million over five years for the partners of the Global HIV Vaccine Enterprise, leading to the creation of the Gates-funded Collaboration for AIDS Vaccine Discovery (CAVD). In 2006 the Bill & Melinda Gates Foundation selected IAVI to be among the first 16 organizations to receive grant funding under the CAVD to accelerate HIV vaccine development. Since the inception of the CAVD, the Foundation has continued to support collaborative HIV research endeavors of IAVI’s Neutralizing Antibody Center. This support has led to many advances, including first-in-human clinical trials of promising new HIV vaccine antigens.

In 2013, the Foundation partnered with the Government of Japan and a group of pharmaceutical companies to launch the Global Health Innovation and Technology Fund (GHIT Fund) to harness Japanese innovation to address diseases that disproportionately affect low- and middle-income countries. Later that year, the Foundation awarded IAVI a grant to create the Vaccine Product Development Center (VxPDC) to assist investigators affiliated with the Foundation’s CAVD with the complex process of transitioning vaccine candidates from the laboratory to the clinic. The CAVD has continued to support the VxPDC to expedite the development of about a dozen promising HIV vaccine candidates and biologics toward clinical testing.

The Bill & Melinda Gates Foundation continues to be a key supporter of IAVI’s mission to translate scientific discoveries into affordable, globally accessible public health solutions.

The Bill & Melinda Gates Foundation congratulates IAVI on its 25th anniversary and the organization’s pioneering approach to working with public and private sectors. IAVI has been a key partner to the Foundation on HIV vaccine development since the first grant in 1999, consistently advancing our shared mission to ensure scientific discoveries lead to public health solutions for people and communities in low- and middle-income countries.

Nina Russell, M.D., director, TB & HIV Prevention, Bill & Melinda Gates Foundation



IAVI and the Coalition for Epidemic Preparedness Innovations (CEPI) began a partnership in 2018 to develop IAVI’s rVSVΔG-LASV-GPC, a replicating viral vector-based vaccine candidate against Lassa fever virus, together with a consortium of partners in West Africa.

CEPI provided US$10.4 million to support the first phase of the project, with options for additional investments over five years for product manufacturing and stockpiling if the novel candidate shows good preliminary results. This support was provided based on previous findings that the vaccine induced strong immune responses and was highly efficacious in animal models.

In June 2021, funding from CEPI played a pivotal role in the launch of the Lassa Fever Vaccine Efficacy and Prevention for West Africa (LEAP4WA) consortium, an international collaboration between Europe, West Africa, and the U.S. to conduct a Phase IIb clinical trial of this Lassa fever vaccine candidate, following a successful completion of the Phase I trial, which launched in July 2021.

This research is a key part of CEPI’s recently launched $3.5 billion plan to tackle future epidemics and pandemics, which includes the goal of advancing clinical trial capacity, infrastructure, and expertise in low- and middle-income countries. The forward-looking plan also aims to advance a Lassa vaccine to licensure within the next five-year period (2022-2026).

IAVI is an instrumental partner for CEPI, in the accomplishment of its mission to accelerate vaccine development for emerging infectious diseases, applying over 25 years of expertise in HIV vaccine research towards the development of a vaccine against Lassa fever. This partnership will help to leverage lessons learned during the COVID-19 response to accelerate vaccine development for emerging infectious diseases. Through our partnership, IAVI also brings decades of experience in strengthening research and clinical trial capacity in sub-Saharan Africa to new partners in West Africa. We look forward to our continued collaboration to develop new globally accessible vaccines for a safer world.

Frederik Kristensen, deputy CEO, CEPI


European & Developing Countries Clinical Trials Partnership (EDCTP)

IAVI recognizes the European & Developing Countries Clinical Trials Partnership (EDCTP) for its continued commitment to supporting Europe and sub-Saharan Africa research collaborations and capacity building that work to accelerate the development and uptake of new and improved clinical interventions to combat HIV/AIDS, tuberculosis, and other infectious and neglected diseases.

The EDCTP has a long history of supporting programs by IAVI and its clinical research partners throughout its two terms. Under EDCTP1 program (2007-2013), as part of a consortium, IAVI provided in-kind support for a project aimed at strengthening long-term capacity for Phase II/III trials of HIV vaccine candidates in Uganda and Malawi through the development of a research network with collaborating institutions in Europe. The study served to prepare remote fishing communities for future HIV prevention and vaccine trials and eventually led to establishing the Lake Victoria Consortium for Health Research.

Under EDCTP2 (2014-2024), the GREAT consortium (Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership), in which IAVI is a partner, received funding to test an improved prototype HIV vaccine in high-risk and vulnerable African populations. Additionally, IAVI is currently providing in-kind support to the EDCTP2-funded Phase IIb/III PrEPVacc trial. This is the first study to test whether a combination of PrEP and an experimental vaccine can prevent HIV infection in African population/people. Additionally, in 2020, IAVI announced the initiation of UPTAKE, an innovative behavioral science research project with support from EDCTP2, which seeks to accelerate future uptake of and adherence to HIV prevention technologies and multi-purpose prevention technologies to prevent HIV and unwanted pregnancy among girls and young women in sub-Saharan Africa.

Beyond HIV prevention, a consortium in which IAVI is a partner received support from EDCTP2 for the development of a novel tuberculosis (TB) vaccine in 2019. The clinical trial is an innovative Phase IIb efficacy trial, using the prevention of TB recurrence post-TB treatment as an indicator of the ability of a vaccine to prevent TB disease in the broader healthy population. Further, with support from CEPI and EDCTP2, a joint project called Lassa Fever Vaccine Efficacy and Prevention for West Africa (LEAP4WA) was announced in July 2021 to conduct advanced clinical development of IAVI’s Lassa fever vaccine candidate among adults and children in Liberia, Nigeria, and Sierra Leone.

You can learn more about the EDCTP’s support here.

EDCTP is pleased to partner with and support strategic partners such as IAVI to advance the development of vaccines to prevent HIV/AIDS as well as other major global health threats, such as tuberculosis (TB) and Lassa fever. IAVI and EDCTP’s track record in cross-disease collaboration and capacity strengthening with partners across sub-Saharan Africa demonstrates unity of mission to support regional leadership to develop innovative solutions to address poverty-related and emerging infectious diseases that are accessible for the people who need them most. 

Michael Makanga, executive director, EDCTP 


The Government of Denmark

IAVI recognizes the Danish government for its continued commitment to HIV vaccine research and applauds the dedication of the Danish Ministry of Foreign Affairs — through the Danish International Development Agency (Danida) — to global health research and development. Since 2001, the Danish government has remained a long-time partner for IAVI in the mission to develop a safe, effective, and accessible HIV vaccine.

As one of IAVI’s founding donors, the Danish government, administered by Danida, has invested a total of DKK 142.5 million since 2001 to further capacity building and engagement of communities most at risk of HIV/AIDS, including women, girls, and key populations. This support most recently included a generous grant of DKK 20 million (US$3.18 million) from 2018-2021.

By supporting IAVI’s work to end the HIV epidemic through new prevention tools, Denmark is continuing to advance progress in the United Nations Sustainable Development Goals agenda and particularly in achieving a healthier and more equitable future for all. Furthermore, the support of IAVI’s HIV vaccine development program advances the joint mission of IAVI and Denmark to promote equitable access to health technologies and services, as well as promoting sexual and reproductive health and rights for women and girls.

As part of this effort, IAVI also acknowledges AIDS-Fondet, its Danish civil society partner since 2001, for its leadership in facilitating HIV vaccine advocacy in Denmark and around the world and for being a highly effective partner in the dialogue with Danida and other key stakeholders in Denmark.

You can learn more about the government of Denmark’s support here.

Denmark wishes to recognize the important role IAVI plays in the development of HIV vaccines and prevention technologies and for reaching out to key populations such as women and girls in order to achieve a world free from AIDS where no one is left behind.

Marianne Kress, head of Department for Migration, Stabilization and Fragile States


The Government of India

IAVI recognizes the Government of India for their unwavering support of the development of safe, effective, accessible, preventive HIV vaccines and biomedical prevention products for use throughout the world.

IAVI’s India program, established in 2001, began through an agreement with the Indian Council of Medical Research, Ministry of Health and Family with the goal of ensuring that India becomes a regional center of excellence in the research and development of vaccines. Steadfast support from the Government of India (GOI) continues to expand IAVI’s life-saving work in India, especially related to HIV.

IAVI’s longstanding partnership with various arms of the GOI has facilitated the creation of innovative national and bilateral programs that are redefining the boundaries for biomedical innovation. Through a unique mix of in-house technical expertise and a robust global network, IAVI has helped pioneer new models of multidisciplinary, multi-sectoral, and multi-regional collaboration to strengthen the country’s value proposition as a model worth emulating for the development of novel biomedical products by and for the global South.

Work with HIV has now translated to the COVID-19 response. IAVI is working as knowledge partner to support implementation of the Mission COVID Suraksha with DBT, a time critical initiative to ensure accelerated development of COVID-19 vaccines.

IAVI is grateful for the longstanding support of the Government of India and is proud to continue to work together to develop health technologies to combat HIV/AIDS, COVID-19, and other emerging infectious diseases, and improve the health of communities most impacted.

You can learn more about the the Government of India’s support here.


The Government of Japan

IAVI recognizes the government of Japan’s continued commitment to HIV vaccine research and most recently COVID-19 vaccine research and applauds their leadership in the fight against infectious diseases.

IAVI has been engaging with policymakers, scientists, and HIV activists in Japan since 2001 to mobilize scientific, political, and financial resources to support HIV vaccine development. In 2010, the government of Japan, in partnership with the World Bank, which has been a key partner since IAVI was founded, supported the development of IAVI’s first HIV vaccine candidate using a replicating vector. The candidate, based on the Japan-originated Sendai virus vector technology, has been tested in Rwanda, Kenya, and the U.K. The novel vaccine trials resulted in building regulatory and clinical research capacity with IAVI’s partners in Africa.

After the Sendai program concluded in 2015, Japan continued to support IAVI’s HIV vaccine work focused on the vesicular stomatitis virus (VSV) technology informed by experience and learning from the Sendai program. Japan’s support of the IAVI VSV program has enabled this platform technology to be applied to a range of pressing global health threats, now including COVID-19. In 2020, the government of Japan announced its commitment to contribute US$10 million to IAVI’s COVID-19 vaccine development.

Japan’s investment in HIV vaccine research and development is just one example of Japan’s longstanding leadership in global health. The Kyushu-Okinawa G8 Summit hosted by Japan in 2000 laid the groundwork for the eventual establishment of The Global Fund to Fight AIDS, Tuberculosis and Malaria. Today, The Global Fund accounts for approximately one-fifth of international financial commitment for HIV, and about two-thirds for TB and malaria. Over the years, Japan has consistently been one of the top donors to The Global Fund.

Similarly, Japan has been a steadfast champion for Universal Health Coverage (UHC) and led the global advocacy that culminated in the United Nations High-Level Meeting on UHC in 2019. Moreover, Japan is a key supporter of the global TB response, co-hosting the 2018 United Nations High-Level Meeting on TB.

You can learn more about the the Government of Japan’s support of IAVI here.

I would like to extend my whole-hearted congratulations on IAVI’s 25-year anniversary. IAVI has made an excellent contribution to cutting-edge research and development in global health, in close partnership with the World Bank Group and the Government of Japan. We look forward to continued collaboration with IAVI for enhancing pandemic preparedness and human capital development. 

Takashi Miyahara, World Bank Group Executive Director representing Japan


The Government of the Netherlands

IAVI recognizes the Ministry of Foreign Affairs of the Netherlands (Ministerie van Buitenlandse Zaken – BuZa) for its continued support for the development of HIV vaccines and other prevention tools, as part of its commitment to provide women, girls, and other groups at high risk of HIV infection with effective and accessible tools for HIV prevention, treatment, and care.

BuZa became a founding donor of IAVI in 1999 when the Netherlands joined the U.K. government in providing the earliest government support for a new public-private partnership initiative. Generous support through the Dutch Minister for Foreign Trade & Development has helped IAVI to spur HIV/AIDS vaccine research through testing innovative concepts and shaping a robust pipeline of HIV vaccine candidates. Moreover, this support has helped IAVI to develop novel international partnerships across the public and private sector, and engage in capacity strengthening and community engagement, particularly in eastern and southern Africa and India, to help accelerate the research. Further, this has facilitated efforts to increase support and demand for HIV vaccines by engaging a broad platform of stakeholders and advocacy allies.

Currently, through the Product Development Partnerships Fund (PDP III), the Ministry supports IAVI’s HIV vaccine research programs through 2021. The PDP III Fund aims to develop cheaper and more effective preventive drugs, vaccines, and diagnostic tools for poverty-related diseases that are common in low- and middle-income countries, but that hold little interest for the regular pharmaceutical industry. The PDP III Fund has also cultivated ongoing IAVI strategic collaborations with Dutch private sector companies Janssen Vaccines and Batavia Biosciences as well as with Dutch academic researchers at the Amsterdam Medical Centre and Erasmus Medical Centre.

Dutch support has also helped IAVI engage in groundbreaking research into powerful antibodies that can target a broader diversity of HIV subtypes. Today these antibodies are a major focus in research, including for the development of novel HIV vaccines and for use as novel products for HIV prevention and cure.

You can learn more about the government of the Netherland’s support here.

We would like to thank IAVI for our long-standing partnership and for dedicating 25 years to the prevention of HIV infection and contributing to accessible and affordable public health solutions for all women, girls, boys and men regarding other major health challenges that mostly affect vulnerable populations in developing countries.

Pascalle Grotenhuis, Ambassador for Women’s Rights and Gender Equality, Ministry of Foreign Affairs, Netherlands


The Government of Norway

IAVI recognizes the Norwegian government for its continued commitment to HIV vaccine research and applauds its dedication to global health research and development.

The Norwegian government has been a longstanding supporter of IAVI’s mission and work. Between 2001 and 2015, through the Norwegian Development Agency (Norad), Norway generously provided IAVI flexible funding for HIV vaccine research (nearly US$30 million) through its support of international product development partnerships. As a founder of the Coalition for Epidemic Preparedness Innovations (CEPI), an innovative partnership between public, private, philanthropic, and civil organizations founded in Davos in 2017 to develop vaccines to stop future epidemics, Norway’s investment and leadership in CEPI continues to fuel work by IAVI and partners to solve other pressing public health challenges as part of a global health security agenda, including the development of IAVI’s replicating viral vector-based Lassa fever vaccine candidate, rVSVΔG-LASV-GPC, as one of the key candidates in CEPI’s portfolio to address emerging infectious diseases (such as Lassa fever).

Most recently, IAVI has received funding through the Research Council of Norway from its Global Health and Vaccination Research (GLOBVAC) program for its innovative development of broadly neutralizing antibodies as HIV prevention products for women and girls in low- and middle-income countries (LMICs). Teams on three continents are working to engineer and optimize antibodies to extend their half-life, an improvement designed to increase the duration of antibody activity and potentially lead to longer intervals between protective doses. These improvements could lead to lower costs and make this HIV prevention technology more affordable and accessible for people in LMICs. The consortium, led by the University of Oslo and with IAVI offices in the U.S. and India being a partner, received a research grant of about $2.2M for a period of three years (2018-2021).

You can learn more about the Government of Norway’s support here.


United States Agency for International Development (USAID)

IAVI recognizes the United States Agency for International Development (USAID), through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), for their 20 years of unwavering support to drive the development of safe, effective, accessible, preventive HIV vaccines and biomedical prevention products for use throughout the world while strengthening local clinical research capacity in regions most devastated by the HIV epidemic.

USAID’s sustained and early investments in HIV vaccine research and development have transformed the field, with resulting data from research protocols now informing the next generation of HIV vaccine and prevention product candidates. Together with USAID, IAVI and our partners have fueled fundamental contributions to understanding the epidemiology, transmission, virology, and immunology of HIV. This work plays a key role in facilitating the design of promising HIV prevention product candidates, as well as the discovery of broadly neutralizing antibodies that are now being advanced as promising prevention approaches to epidemic control.

Most recently, ADVANCE (Accelerate the Development of Vaccines and New Technologies to Combat the AIDS Epidemic), a 10-year cooperative agreement with USAID through PEPFAR, builds on IAVI’s long-term partnership with USAID and capitalizes on the IAVI-fostered, sustainable, Africa- and India-based research partner network to build self-reliance. Concurrently, linkages from civil society to governments continue to create enabling policy and regulatory for HIV vaccine research and investment by countries most impacted by the epidemic.

Today, USAID’s integrated development and partnership capability in HIV prevention enables IAVI ’s expansion to address other unmet public health needs – such as COVID-19, Ebola, Lassa fever, snakebite, tuberculosis, antimicrobial resistance, and Marburg virus – thanks to the strength of the clinical and laboratory infrastructure built throughout this legacy partnership.

Through its longstanding partnership with IAVI, USAID has fulfilled the United States’ Congressional Directive to contribute to the search for a safe and effective, preventive HIV vaccine in partnership with key African institutions who must lead these endeavors going forward. We know the American people can count on IAVI and its partners to pursue this critically important tool with a sense of urgency as the HIV pandemic cannot be conquered without such a biomedical tool.

Margaret McCluskey, Senior Technical Advisor for Vaccines, USAID Office of HIV/AIDS